Insights
Recon takes an analytical look behind select developments in healthcare
Keep up with Recon Strategy Insights
Get an email each time we publish a new article
Search
- By Marc Herant
Successes in gene therapy for hemophilia B and A
Hemophilia A and B are X-linked genetic diseases which prevents the formation of functional coagulant factors VII and IX respectively and cause a prope…
- By Tory Wolff
OptumHealth and its proposed acquisition target DaVita Medical Group (DMG) have a lot in common:
Ambulatory care portfolios: physician practices, urgent care centers and ambulatory surgical centers (…
- By Tory Wolff
Who will be the first to take integrated health care delivery national?
A few years ago, the best bet might have been an established provider with a nationally compelling brand and a growing affiliate…
- By Marc Herant
Two new therapies against a horrible congenital disease – but trouble ahead on pricing…
Spinal Muscular Atrophy (SMA) is a genetic disease that declares itself at a few months of age, and typically le…
- By Tory Wolff
UPMC’s recent spectacular deal-making careen through central Pennsylvania (picking up the big Susquehanna and Pinnacle systems as affiliates and Tower as a joint venture partner all in under a year) c…
- By Marc Herant
Between the very common and the very rare – An opinionated take on NEJM highlights for October 2017
Another tool for prevention in cardiovascular disease
Taking aspirin daily has been standard of ca…
- By Tory Wolff
Back in 2013, Dignity and Optum formed a joint venture for revenue cycle management (RCM) services named Optum360. Dignity contributed processing centers and 1,700 employees in return for ~25% share i…
- By Marc Herant
A new drug to address hard-to-treat severe asthma
In ~10% of people with asthma, traditional therapies do not work well and they have recurrent exacerbations leading them to the ED. Over the past few …
- By Marc Herant
At last, drug prices influence physician usage patterns
Association of Reference Pricing with Drug Selection and Spending (subscriber access); Nitroprusside and Isoproterenol Use after Major Price Inc…